600222.SHG Henan Taloph Pharmaceutical Stock Co Ltd
- Market cap
- CNY 3.74B
- P/E
- 74.3x
- P/B
- 2.26x
- ROE
- 1.3%
- Dividend yield
- 1.36%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600222.SHG undervalued?
Graham number600222.SHG trades 173.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Henan Taloph Pharmaceutical Stock Co Ltd fundamental analysis
No fundamental analysis for Henan Taloph Pharmaceutical Stock Co Ltd yet.
Henan Taloph Pharmaceutical Stock Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Henan Taloph Pharmaceutical Stock Co Ltd
Henan Taloph Pharmaceutical Stock Co.,Ltd engages in the manufacture and sale of pharmaceutical preparations and Chinese herbal medicine slices in China. The company offers Shuanghuanglian oral liquid series, Shuangjinlian mixture, children's heat-clearing and cough-relieving oral liquid series, pediatric antipyretic oral liquid, Jiaweishanxiang Zhengqi compound preparation, honeysuckle dew, danshen oral liquid, Shengmai Yin, pediatric compound chicken gizzard chewable table…
Full company profileHenan Taloph Pharmaceutical Stock Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Henan Taloph Pharmaceutical Stock Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 953M | 1.17B | 1.19B | 1.31B | 1.42B | 1.60B | 1.96B | 2.07B | 1.94B | 1.76B | 1.51B |
| Gross Profit | 307M | 355M | 400M | 482M | 371M | 457M | 468M | 562M | 500M | 492M | 347M |
| Operating Income | 7.36M | 21.9M | 73.7M | 50.5M | 33.0M | 35.6M | -70.8M | 44.2M | 35.7M | 163M | 84.5M |
| EBITDA | 63.9M | 61.4M | -5.59M | 85.5M | 146M | 57.2M | 30.2M | 95.2M | 148M | 197M | 91.5M |
| Net Income | 4.02M | 5.13M | -115M | 44.4M | 29.2M | 6.00M | -72.2M | 43.6M | 50.5M | 60.0M | 21.6M |
| EPS | 0.01 | 0.01 | -0.20 | 0.08 | 0.05 | 0.01 | -0.13 | 0.08 | 0.09 | 0.10 | 0.04 |
| Balance Sheet | |||||||||||
| Total Assets | 2.65B | 2.81B | 2.84B | 2.74B | 3.39B | 3.78B | 3.60B | 3.58B | 3.49B | 3.64B | 3.76B |
| Total Liabilities | 1.15B | 1.30B | 1.44B | 1.43B | 1.86B | 2.01B | 1.99B | 1.95B | 1.86B | 1.98B | 2.08B |
| Shareholders' Equity | 1.48B | 1.49B | 1.39B | 1.38B | 1.45B | 1.66B | 1.57B | 1.58B | 1.57B | 1.60B | 1.62B |
| Cash & Short-term Investments | 586M | 669M | 800M | 574M | 695M | 666M | 386M | 350M | 260M | 224M | 273M |
| Total Debt | 964M | 1.06B | 1.19B | 1.14B | 1.32B | 1.18B | 666M | 819M | 678M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 70.6M | 23.2M | 119M | 41.5M | 73.4M | 99.7M | -124M | 43.7M | -39.6M | 47.2M | - |
| Capital Expenditure | 59.6M | 44.3M | 66.4M | 108M | 72.7M | 39.1M | 66.6M | 43.1M | 37.2M | 21.1M | 10.1M |
| Free Cash Flow | 11.0M | -21.2M | 53.1M | -64.0M | 775K | 60.6M | -191M | 604K | -76.8M | 26.0M | -129M |
| Ratios | |||||||||||
| ROE | 0.3% | 0.3% | -8.3% | 3.2% | 2.0% | 0.4% | -4.6% | 2.8% | 3.2% | 3.7% | 1.3% |
| ROA | 0.2% | 0.2% | -4.1% | 1.6% | 0.9% | 0.2% | -2.0% | 1.2% | 1.4% | 1.6% | 0.6% |
| Net Profit Margin | 0.4% | 0.4% | -9.7% | 3.4% | 2.1% | 0.4% | -3.7% | 2.1% | 2.6% | 3.4% | 1.4% |
| Debt to Equity | 0.65x | 0.71x | 0.86x | 0.83x | 0.91x | 0.71x | 0.42x | 0.52x | 0.43x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Henan Taloph Pharmaceutical Stock Co Ltd dividends
- Dividend yield
- 1.36%
- Forward dividend
- 0.01 CNY
- Payout ratio
- 84.6%
- Ex-dividend date
- Jan 9, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 50.8M | 0.09 | 84.6% |
| 2024 | CNY 69.1M | 0.12 | 136.7% |
| 2023 | CNY 50.2M | 0.09 | 115.2% |
| 2022 | CNY 5.63M | 0.01 | - |
| 2021 | CNY 84.6M | 0.15 | 1,410.3% |
| 2020 | CNY 65.5M | 0.12 | 223.9% |
| 2019 | CNY 60.0M | 0.11 | 135.1% |
| 2018 | CNY 67.0M | 0.12 | - |
| 2017 | CNY 55.6M | 0.10 | 1,084.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 13:10 on May 12, 2010.
Who owns Henan Taloph Pharmaceutical Stock Co Ltd
- Insiders 30.04%
- Institutions 1.59%
- Public & others 68.37%
- Shares outstanding 559M
- Free float 411M
Henan Taloph Pharmaceutical Stock Co Ltd company profile
- Company name
- Henan Taloph Pharmaceutical Stock Co Ltd
- Ticker
- 600222.SHG
- ISIN
- CNE0000010L8
- Exchange
- Shanghai Stock Exchange
- Listed since
- Aug 13, 1999
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,084
- Fiscal year end
- December
- Address
- No. 8 Jinsuo Road, Zhengzhou, China, 450001
- Phone
- 86 03 7167 982194
- Website
- taloph.com
About Henan Taloph Pharmaceutical Stock Co Ltd
Henan Taloph Pharmaceutical Stock Co.,Ltd engages in the manufacture and sale of pharmaceutical preparations and Chinese herbal medicine slices in China. The company offers Shuanghuanglian oral liquid series, Shuangjinlian mixture, children's heat-clearing and cough-relieving oral liquid series, pediatric antipyretic oral liquid, Jiaweishanxiang Zhengqi compound preparation, honeysuckle dew, danshen oral liquid, Shengmai Yin, pediatric compound chicken gizzard chewable tablets, Chewable tablets, huperzine A tablets, Wuzi Yanzong oral liquid, compound motherwort oral liquid, etc. It is also involved in pharmaceutical research and development, and medicine and medicinal materials distribution. The company's medicine preparations are used in the treatment of respiratory system, cardiovascular and cerebrovascular, digestive system, nervous system, menstrual system, reproductive system, and gynecological diseases. Henan Taloph Pharmaceutical Stock Co.,Ltd was formerly known as Henan Joyline & Joysun Pharmaceutical Stock Co., Ltd. The company was founded in 1998 and is based in Zhengzhou, China.
Henan Taloph Pharmaceutical Stock Co Ltd management
5- Mr. Jingliang LiGM & Vice Chairman · born 1969
- Mr. Hailin ZhaoCFO & Deputy GM · born 1975
- Mr. Fengshan SuExecutive Vice General Manager · born 1977
- Ms. Nianyun LiDeputy GM & Secretary · born 1991
- Mr. Lizhuang ZhangDeputy General Manager · born 1966